Today 23andMe announced the launch of its new Genotyping Services for Research (GSR) platform, providing scientists with an end-to-end service to incorporate genetic information into their studies.
23andMe, Inc., the leading personal genetics company, today announced that the National Institutes of Health (NIH) has funded a promising new study by scientists at 23andMe that could help alleviate some of the existing disparities in genetic research between people of European ancestry and people of African, Latino and Asian ancestry.
23andMe today announced a new ResearchKit module that allows researchers to seamlessly integrate genetic information into their app-based studies. ResearchKit, an open source software framework designed by Apple, makes it easy for researchers to create studies for iPhone.
23andMe, Inc., the leading personal genetics company, today announced the results of one of the largest genome-wide association studies of its kind, identifying genetic variants associated with being a morning person. Published in Nature Communications the study identified 15 locations in DNA (loci) associated with “morningness.”
23andMe, Inc., the leading personal genetics company, today announced that its service is now completely available to people both in New York and Maryland. Previously, customers in New York could not ship saliva samples from the state, while state law in Maryland prohibited direct-to-consumer genetic testing all together.
23andMe, Inc., the leading personal genetics company, today announced the launch of their new Personal Genome Service (PGS). Following two years of work with the FDA, extensive user comprehension testing and a complete redesign, 23andMe is launching an entirely new experience that includes carrier status, wellness, trait and ancestry reports.
23andMe, Inc., the leading personal genetics company, today announced it has raised $115 million in a Series E financing led by Fidelity Management & Research Company.
23andMe, Inc. today announced the appointment of Dean Schorno, CPA, as chief financial officer and head of operations for the company. In his new role, Schorno will oversee 23andMe’s global financial and clinical laboratory operations.
23andMe, Inc., the leading personal genetics company, today announced it has genotyped more than one million people worldwide. By accessing their own DNA to learn more about themselves, 23andMe customers have helped push genetic testing into the mainstream, and helped power a new genetic research model.
The three-time Emmy® award-winning, The Dr. Oz Show announced today the hiring of Michael Crupain, M.D., as Chief Of Staff of the Medical Unit. Dr. Crupain will lead the section of the show’s production responsible for researching and vetting scripts, evaluating expert guests, ordering and editing medical animations and overseeing liaisons with the show’s Medical Advisory Board. He will also lead efforts to enhance the show’s ongoing dialogue with the medical community.
23andMe, Inc., the leading personal genetics company, today announced the launch of the Lupus Research Study in collaboration with Pfizer Inc. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort is also in collaboration with the Lupus Research Institute, and in concert with Lupus Awareness Month in May.
Bioinformatics Pioneer Robert Gentleman, Ph.D., Joins 23andMe Leadership Team
23andMe, the leading personal genetics company, today announced the appointment of Erynn Gordon, MS, CGC as medical marketing director.
23andMe today announced the creation of a new therapeutics group and appointment of Richard Scheller, Ph.D. as chief science officer and head of therapeutics to lead it. Dr. Scheller retired in December 2014 from a distinguished 14 year career as an executive at Genentech where he was the executive vice president of research and early development.
Today marked the publication of the first ever genome-wide association study of rosacea, a common and incurable skin disorder. Led by Dr. Anne Lynn S. Chang of Stanford University’s School of Medicine, and co-authored by 23andMe, the study is the first to identify genetic factors for this condition.
23andMe, the leading personal genetics company, today announced the appointment of Kate Black as Privacy Officer and Corporate Counsel. Black brings a strong background in international, federal, and state privacy laws as well as health care regulations. As a member of the legal and regulatory team, she will be responsible for reviewing, updating and enhancing the company’s privacy and consent policies for customers in the U.S. and abroad. She joined the company January 5, 2015 and reports to Kathy Hibbs, chief legal and regulatory affairs officer.
23andMe has been granted authority by the U.S. Food and Drug Administration (FDA) to market the first direct-to-consumer genetic test under a regulatory classification for novel devices.
Data by 23andMe links motion sickness to 35 genetic variants.
23andMe and Pfizer collaborate to establish new lupus research community.
23andMe and Genentech are partnering to analyze the genetic patterns associated with Parkinson's Disease.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right